SCHEMBL1480753

SCHEMBL1480753

FC(F)(F)Oc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)c[nH]3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.40
MARS1 P56192 1/20 0.40
DHODH Q02127 1/20 0.39
ALOX5 P09917 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
ACLY P53396 2/20 0.35
HPSE Q9Y251 1/20 0.34
CHRNA7 P36544 1/20 0.34
GRIN2B Q13224 1/20 0.34
EGFR P00533 1/20 0.34
EIF4E P06730 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
RECQL P46063 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480749 1.00 TRPV1 (0.40) TRPV1MARS1DHODHALOX5CCNT1
SCHEMBL1481234 0.91 PTGES (0.38) TRPV1MARS1DHODHACLY
SCHEMBL1481232 0.91 PTGES (0.38) TRPV1MARS1DHODHACLY
SCHEMBL6526587 0.87 PTGES (0.36) TRPV1MARS1DHODHACLY
SCHEMBL6526590 0.87 PTGES (0.36) TRPV1MARS1DHODHACLY
SCHEMBL1481070 0.86 MAPT (0.44) MARS1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1481066 0.86 MAPT (0.44) MARS1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1480751 0.84 MCL1 (0.40) DHODHALOX5MAPTMAPK1MEN1
SCHEMBL1480754 0.84 MCL1 (0.40) DHODHALOX5MAPTMAPK1MEN1
SCHEMBL1480764 0.83 PTGES (0.44) TRPV1MAPTMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ TRPV1 3437/4885MARS1 3703/4885DHODH 568/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ TRPV1 3437/4885MARS1 3703/4885DHODH 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.